Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT02420691
• Collaborator: National Cancer Institute (NCI) (NIH), Novartis (Industry)
• Enrollment: 21
• Location: 1
• Arm: 1
• Actual Duration (Months): 45.3
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced tumors). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or Disease	Intervention/Treatment	Phase
Advanced Digestive System Neuroendocrine Neoplasm; Duodenal Neuroendocrine Tumor G1; Functional Pancreatic Neuroendocrine Tumor; Gastric Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Nonfunctional Pancreatic Neuroendocrine Tumor; Thymus Neoplasm	Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Ribociclib	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To estimate the Response Evaluation Criteria in Solid Tumors (RECIST) (per version 1.1) objective response rate of LEE011 (ribociclib) among patients with advanced foregut neuroendocrine tumors (NETs).

SECONDARY OBJECTIVES:

1. To evaluate the progression free survival duration of LEE011 among patients with advanced foregut NETs.

2. To evaluate the safety and tolerability of LEE011 in patients with advanced foregut NETs.

3. To determine clinic benefit rate at 6 months (defined as complete response plus partial response plus stable disease) with LEE011 among patients with advanced foregut NETs.

EXPLORATORY OBJECTIVES:

1. To determine baseline molecular markers (mutations, deletions, and amplifications in multiple endocrine neoplasia [MEN]1, p27, p16 and cyclin D1 [CCND1]) in archival tumor that may predict clinical benefit at 6 months from LEE011.

2. To determine potential mechanisms/markers of resistance. III. To determine early chromogranin and neuron specific enolase responses in patients with elevated levels at baseline.

3. To determine the pharmacodynamic changes including proliferation-related Ki-67 antigen (Ki-67) and phosphorylated retinoblastoma (pRb) upon treatment with LEE011 in patients with advanced foregut NETs.

OUTLINE:

Patients receive ribociclib orally (PO) once daily (QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Study Design

• Study Type: Interventional
• Actual Enrollment: 21 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin
• Actual Study Start Date: Aug 25, 2015
• Actual Primary Completion Date: Jun 5, 2019
• Actual Study Completion Date: Jun 5, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (ribociclib) Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Other: Laboratory Biomarker Analysis; Correlative studies; Other: Pharmacological Study; Correlative studies; Drug: Ribociclib; Given PO; Other Names: Kisqali LEE-011 LEE011

Outcome Measures

Primary Outcome Measures

1. Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1 [3 years 10 months]

   Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Secondary Outcome Measures

1. Number of Participants With Clinical Benefit Rate [At 6 months]

   Number of Participants that did not have progressive disease at 6 months.

2. Progression Free Survival (PFS) [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 24 months]

   PFS is the length of time during and after the treatment that a participant lives with the disease but it does not get worse.The Kaplan-Meier (KM) method will be used to estimate the PFS.

Other Outcome Measures

1. Change in pRB With Treatment [Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days]

   Decrease in pRB as Measured by Immunohistochemistry (IHC) in Biopsies From Baseline and From cycle 2 day 1. H-scores were calculated as the sum of the products of the percentage of positive staining areas and the staining intensity (0, 1, 2 or 3), and ranged from 0 to 300. A score of 0 represents the absence of expression, and an H-score of 300 represents maximum expression.

2. Change in Ki-67 With Treatment [Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days]

   Ki-67 was calculated as a percentage cells staining positive by Immunohistochemistry (IHC).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Histologically or cytologically confirmed low or intermediate grade, unresectable well differentiated foregut neuroendocrine tumors (thymic, bronchopulmonary, gastric, duodenal and pancreatic); patients with multiple neuroendocrine tumors associated with MEN1 syndrome will be eligible

• Patients must have radiographically measurable disease

• Pancreatic neuroendocrine patients must have had progression after prior therapy; patients with other foregut neuroendocrine tumors must have had progressive disease over the last 12 months, irrespective of prior therapy; patients with both functional (who may continue somatostatin analogues as required for control of related symptoms) and non-functional tumors are eligible; in patients who have previously received therapy, the number of prior lines of therapy should not be more than 2 lines of systemic therapy not including somatostatin analogues

• Written informed consent must be obtained prior to any screening procedures

• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

• A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies and major surgery) and enrollment, to allow the effects of prior therapy to have abated: a) cytotoxic or targeted chemotherapy: greater than or equal to the duration of the cycle of the most recent treatment regimen (a minimum of 3 weeks for all regimens, except 6 weeks for nitrosoureas and mitomycin-C); b) biologic therapy (e.g., antibodies): greater than or equal to 4 weeks

• Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L

• Hemoglobin (Hgb) greater than or equal to 9 g/dL

• Platelets greater than or equal to 100 x 10^9/L

• Serum total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) less than or equal to 2.5 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT less than or equal to 5 x ULN

• Serum creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or equal to 50 mL/min

• Serum potassium (corrected for serum albumin) must be within clinically relevant limits (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory range but the abnormality is not clinically relevant or can be repleted)

• Sodium (corrected for serum albumin) must be within clinically relevant limits (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory range but the abnormality is not clinically relevant or can be repleted)

• Magnesium (corrected for serum albumin) must be within clinically relevant limits (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory range but the abnormality is not clinically relevant or can be repleted)

• Phosphorus (corrected for serum albumin) must be within clinically relevant limits (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory range but the abnormality is not clinically relevant or can be repleted)

• Total calcium (corrected for serum albumin) must be within clinically relevant limits (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory range but the abnormality is not clinically relevant or can be repleted)

• Negative pregnancy test (serum beta-human chorionic gonadotropin [B-HCG]) within 7 days of starting study treatment is required in women of childbearing potential; NET patients with positive B-HCG are eligible if pregnancy can be excluded by vaginal ultrasound or lack of expected doubling of B-HCG

Exclusion Criteria:

• Patient has a known hypersensitivity to LEE011 or any of its excipients

• Patients with known or suspected brain metastases; however, if radiation therapy and/or surgery has been completed and serial evaluation by computed tomography (CT) (with contrast enhancement) or magnetic resonance imaging (MRI) over a minimum of 3 months demonstrates the disease to be stable and if the patient remains asymptomatic, then the patient may be enrolled; such patients must have no need for treatment with steroids or anti-epileptic medications

• Patients with concurrent malignancies or malignancies within 3 years prior to starting study drug (with the exception of tumors common to a single genetic cancer syndrome, i.e. MEN1, MEN2, von Hippel-Lindau [vHL], tuberous sclerosis complex [TSC] etc., or adequately treated, basal cell skin cancer, squamous cell carcinoma, non-melanoma skin cancer or curatively resected cervical cancer)

• Patient is not able to swallow oral medication and/or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

• Known diagnosis of human immunodeficiency virus (HIV) or hepatitis C (testing is not mandatory)

• Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in the clinical study (e.g. chronic pancreatitis, chronic active hepatitis, etc.)

• Patient who has received radiotherapy within less than or equal to 4 weeks or limited field radiation for palliation within less than or equal to 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom greater than or equal to 30% of the bone marrow was irradiated

• Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)

• Impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) history of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis less than 12 months prior to screening b) history of documented congestive heart failure (New York Heart Association functional classification III-IV) c) documented cardiomyopathy d) patient has a left ventricular ejection fraction (LVEF) less than 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening e) history of ventricular, supraventricular, nodal arrhythmias, or any other cardiac arrhythmias, long QT syndrome or conduction abnormality within 12 months prior to starting study drug f) congenital long QT syndrome or a family history of corrected QT interval (QTc) prolongation g) on screening, inability to determine the corrected QT for Fridericia (QTcF) interval on the electrocardiogram (ECG) (i.e.: unreadable or not interpretable) or QTcF > 450 msec (using Fridericia's correction); all as determined by screening ECG (mean of triplicate ECGs)

• Systolic blood pressure greater than 160 mmHg or less than 90 mmHg at screening

• Patients who are currently receiving treatment with agents that are known to cause QTc prolongation or inducing Torsade de Pointes in humans and are unable to discontinue or switch to an alternate medication

• Patients who are currently receiving treatment (within 5 days prior to starting study drug) with agents that are known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A polypeptide 4 (CYP3A4)/cytochrome P450, family 3, subfamily A polypeptide 5 (5), or that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5

• Patients with concurrent severe and/or uncontrolled concurrent medical conditions that could compromise participation in the study (e.g., uncontrolled diabetes mellitus defined by a glucose greater than 1.5 ULN in spite of adequate medical treatment, clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection)

• Patient has a history of non-compliance to medical regimen or inability to grant consent

• Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (greater than 5 mIU/mL)

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation; highly effective contraception methods include: total abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment; male sterilization (at least 6 months prior to screening); for female patients on the study, the vasectomized male partner should be the sole partner for that patient; combination of any of the two following (a+b or a+c or b+c) a. use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception b. placement of an intrauterine device (IUD) or intrauterine system (IUS) c. barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository; in case of use of oral contraception, women should have been stable on the same pill before taking study treatment; note: oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception; women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential

• Sexually active males unless they use a condom during intercourse while taking the drug and for 21 days after stopping treatment and should not father a child in this period; a condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid

• Patients unwilling or unable to comply with the protocol

• Patient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	M D Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• National Cancer Institute (NCI)
• Novartis

Investigators

• Principal Investigator: Nageshwara V Dasari, M.D. Anderson Cancer Center

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - May 19, 2015

More Information

Additional Information:

• University of Texas MD Anderson Cancer Center Website

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT02420691
• Other Study ID Numbers: 2014-0371; NCI-2015-01017; 2014-0371; P30CA016672
• First Posted: Apr 20, 2015
• Last Update Posted: Oct 30, 2020
• Last Verified: Oct 1, 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Neoplasms; Neuroendocrine Tumors; Adenoma, Islet Cell; Thymus Neoplasms; Thymoma

Study Results

Participant Flow

Recruitment Details	September 2015-August 2016. All patients enrolled at MD Anderson.
Pre-assignment Detail	21 participants consented, 1 participant was not eligible due to screen failure.

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Period Title: Overall Study
STARTED	20
COMPLETED	14
NOT COMPLETED	6

Baseline Characteristics

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Overall Participants	20
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	15 75%
>=65 years	5 25%
Age (years) [Mean (Full Range) ]
Mean (Full Range) [years]	57
Sex: Female, Male (Count of Participants)
Female	6 30%
Male	14 70%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	3 15%
Not Hispanic or Latino	15 75%
Unknown or Not Reported	2 10%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	1 5%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	1 5%
White	16 80%
More than one race	0 0%
Unknown or Not Reported	2 10%
Region of Enrollment (participants) [Number]
United States	20 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1
Description	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time Frame	3 years 10 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Measure Participants	19
Number [participants]	19 95%

2. Secondary Outcome

Title	Number of Participants With Clinical Benefit Rate
Description	Number of Participants that did not have progressive disease at 6 months.
Time Frame	At 6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Measure Participants	19
Number [participants]	19 95%

3. Secondary Outcome

Title	Progression Free Survival (PFS)
Description	PFS is the length of time during and after the treatment that a participant lives with the disease but it does not get worse.The Kaplan-Meier (KM) method will be used to estimate the PFS.
Time Frame	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Measure Participants	20
Median (95% Confidence Interval) [months]	10.44

4. Other Pre-specified Outcome

Title	Change in pRB With Treatment
Description	Decrease in pRB as Measured by Immunohistochemistry (IHC) in Biopsies From Baseline and From cycle 2 day 1. H-scores were calculated as the sum of the products of the percentage of positive staining areas and the staining intensity (0, 1, 2 or 3), and ranged from 0 to 300. A score of 0 represents the absence of expression, and an H-score of 300 represents maximum expression.
Time Frame	Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Measure Participants	19
H- Score Pre-Treatment	236.47 (67.25)
H-Score Post-Treatment	238.32 (39.56)

5. Other Pre-specified Outcome

Title	Change in Ki-67 With Treatment
Description	Ki-67 was calculated as a percentage cells staining positive by Immunohistochemistry (IHC).
Time Frame	Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
Measure Participants	19
Pre-Treatment	13.61 (10.18)
Post-Treatment	19.11 (17.83)

Adverse Events

Time Frame	3 years and 5 months
Arm/Group Title	Study Participants
Arm/Group Description	LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.
All Cause Mortality
	Study Participants
	Affected / at Risk (%)	# Events
Total	11/20 (55%)
Serious Adverse Events
	Study Participants
	Affected / at Risk (%)	# Events
Total	7/20 (35%)
Blood and lymphatic system disorders
Febrile Neutropenia	1/20 (5%)
Gastrointestinal disorders
Upper Gastrointestinal Hemorrhage	2/20 (10%)
General disorders
Non-cardiac Chest Pain	1/20 (5%)
Metabolism and nutrition disorders
Hypoglycemia	1/20 (5%)
Hypokalemia	1/20 (5%)
Nervous system disorders
Encephalopathy	1/20 (5%)
Renal and urinary disorders
Acute Kidney Injury	2/20 (10%)
Respiratory, thoracic and mediastinal disorders
Pneumothroax	1/20 (5%)
Vascular disorders
Thromboembolic Event	1/20 (5%)
Other (Not Including Serious) Adverse Events
	Study Participants
	Affected / at Risk (%)	# Events
Total	17/20 (85%)
Blood and lymphatic system disorders
Anemia	12/20 (60%)
Cardiac disorders
Palpitations	1/20 (5%)
Eye disorders
Eye Disorders: Other- Periorbital Swelling and Crystal Discharge	1/20 (5%)
Gastrointestinal disorders
Vomiting	5/20 (25%)
Diarrhea	4/20 (20%)
Constipation	2/20 (10%)
Gastroparesis	1/20 (5%)
Abdominal Distention	1/20 (5%)
Gastroesophageal Reflux Disease	1/20 (5%)
Mucositis Oral	1/20 (5%)
General disorders
Fatigue	11/20 (55%)
Edema Limbs	3/20 (15%)
Fever	2/20 (10%)
Malaise	1/20 (5%)
Edema Face	1/20 (5%)
Infections and infestations
Urinary Tract Infection	1/20 (5%)
Upper Respiratory Infection	1/20 (5%)
Skin infection	1/20 (5%)
Investigations
Neutrophil Count Increased	17/20 (85%)
Platelet Count Decreased	9/20 (45%)
Creatinine Increased	8/20 (40%)
Alanine Aminotransferase Increased	4/20 (20%)
Aspartate Aminotransferase Increased	3/20 (15%)
Weight Loss	3/20 (15%)
Alkaline Phosphatase Increased	2/20 (10%)
Blood Bilirubin Increased	2/20 (10%)
Investigations: Other- Hyperphosphatemia	1/20 (5%)
Metabolism and nutrition disorders
Nausea	12/20 (60%)
Anorexia	4/20 (20%)
Hypophosphatemia	2/20 (10%)
Hypomagnesemia	2/20 (10%)
Hyperphosphatemia	1/20 (5%)
Hyperglycemia	1/20 (5%)
Dehydration	1/20 (5%)
Musculoskeletal and connective tissue disorders
Back Pain	1/20 (5%)
Arthralgia	1/20 (5%)
Arthritis	1/20 (5%)
Nervous system disorders
Dysguesia	3/20 (15%)
Headache	2/20 (10%)
Peripheral Sensory Neuropathy	2/20 (10%)
Renal and urinary disorders
Acute Kidney Injury	1/20 (5%)
Respiratory, thoracic and mediastinal disorders
Dyspnea	3/20 (15%)
Nasal Congestion	1/20 (5%)
Skin and subcutaneous tissue disorders
Rash Maculo-papular	3/20 (15%)
Pruritus	2/20 (10%)
Dry Skin	1/20 (5%)
Vascular disorders
Hematoma	1/20 (5%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.